"Walder Wyss Advises ExcellGene and Magellan Biologics on Majority Stake Sale to Archimed"

"Walder Wyss advised ExcellGene and Magellan Biologics & Consulting Global on the sale of a majority stake to Archimed, a private equity healthcare firm. This transaction aims to establish a group focused on gene transfer, cell line development, and cell culture-based manufacturing for the production of recombinant proteins. The Walder Wyss team was led by partner Luc Defferrard, with contributions from various associates and partners in corporate, employment, and tax law."

Walder Wyss advised ExcellGene and Magellan Biologics & Consulting Global on the sale of a majority stake to private equity healthcare specialist Archimed. This transaction aims to establish a group focused on gene transfer, cell line development, and cell culture-based manufacturing for the high-performance production of recombinant proteins. The Walder Wyss team involved in this transaction included Partner Luc Defferrard (corporate/M&A), Senior Associate Caroline Sauthier (corporate/M&A), Associate Matteo Berti (corporate/M&A), Counsel Laura Luongo (employment), Partner Fabienne Limacher (tax), and Associate Daniela Hottiger (tax).

Read the full story

Already registered? Login

"Walder Wyss Advises ExcellGene and Magellan Biologics on Majority Stake Sale to Archimed"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads